# First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

> **NCT04083534** · PHASE1,PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** REGN5459

## Key facts

- **NCT ID:** NCT04083534
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-26
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083534, "First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04083534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*